Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
NT-4 CRISPR/Cas9 KO Plasmid (h): sc-402291
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- NT-4 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the NT-4 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: NT-4 Antibody (C-1): sc-365444
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
NT-4 CRISPR/Cas9 KO Plasmid (h) | sc-402291 | 20 µg | $397.00 |
Overview
Human NTF4 encodes neurotrophin-4 (NT-4), a secreted growth factor in the neurotrophin family that primarily signals through the TrkB (NTRK2) receptor to activate MAPK/ERK, PI3K/AKT, and PLCγ pathways. NT-4 supports neuronal survival, neurite outgrowth, synaptic plasticity, and activity-dependent circuit maintenance, with additional roles reported in sensory systems and peripheral innervation. Dysregulated neurotrophin–TrkB signaling is implicated in neurodegeneration, neurodevelopmental phenotypes, and altered synaptic function, making NTF4 a relevant target for mechanistic studies of neuronal connectivity and trophic support. NTF4 expression and NT-4/TrkB pathway activity are also examined in models of injury responses and stress-related cellular remodeling.
NT-4 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the NTF4 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the NTF4 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the NTF4 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish NT-4 protein expression.
This CRISPR knockout system enables efficient generation of NTF4-deficient cell models for investigation of NT-4 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting NTF4 exon(s) critical for NT-4 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple NTF4 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by NT-4 CRISPR/Cas9 KO Plasmid (h) and NT-4 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the NTF4 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by NT-4 HDR Plasmid (h) and NT-4 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by NTF4 homology arms to support homology-directed repair at defined NTF4 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.